{
  "docId": "019de076-08a6-76d8-a7d9-b68643d71f6f",
  "docSlug": "3a0354fd1e64f16191ffa0e33db132fd",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 19 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 19,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a three-column layout to summarize key value propositions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-08a6-76d8-a7d9-b68643d71f6f/3",
  "deckHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f",
  "deckJsonHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f.json",
  "deckAnchorHref": "/decks/019de076-08a6-76d8-a7d9-b68643d71f6f#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.04,
        "y": 0.0016
      },
      "kind": "list",
      "text": "With 600+ platforms in place, our proprietary technology unlocks the significant potential of advanced therapeutics. Enables delivery of almost any molecule into almost any cell type. Leads the industry in performance. Extensive product portfolio. ~25% 5-Year CAGR; ~89% gross margins.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "272966ac-a001-4a4e-a305-a21a20845eca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.36,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Leading the growing next-generation cell therapy market. 20+ years of expertise. 30+ field sales/scientists. Significant collaborations. FDA Master File. Used in 45+ clinical trials.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ca5008f-dc6d-4114-af27-28f2f3ec4313",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.68,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Innovative business model focused on value creation and shared partnership success. 23 SPL partnerships. $2B in potential pre-commercial milestone payments. Focused on diverse portfolio of patient treatments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e838de30-66d9-4b2a-91f9-2ce9a922698a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.69,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*As of December 31, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "493e6ef8-af87-4883-ac7d-3f606d8e3303",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "A Leading Provider of Cell-Engineering Platform Technologies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ed9d2df-ab7f-460d-98ed-004f300fa4dd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "1a3019d7-2fb3-472b-b796-28256dcf85b1",
      "evidence": "The slide provides a brief overview of the company's technology and business model.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}